FDA Oks Novartis's Zortress For Liver Transplantation – Quick Facts – RTT News
FDA Oks Novartis’s Zortress For Liver Transplantation – Quick Facts
RTT News According to the company, Zortress is the first mammalian target of rapamycin (mTOR) inhibitor approved for use following liver transplantation. It is also … In most EU member countries, Certican is also approved in kidney and heart transplantation … |